Deb. I want to talk very briefly about two or three things. First, the issue of testing and how that has changed the complexion of the approach we are going to be able to take. Testing was an issue, many questions of testing in this room for number of times. Now that we literally have hundreds and hundreds of thousands of testing out there, there are a few things we could do with that. One of the things is when we make policy of what we are going to be doing with the rest of the country, particularly those areas that are not hotspots, we need to know what the infection is there. We need to put a light on those dark spots that we dont know. We have to act policy wise on data. We are going to be getting more data, a lot more data. The other thing is the areas of the country that are not hotspots, that are not going through the terrible ordeal that new york and california and Washington State are going through, they still have a window of significant degree of being able to contain. In ot
Safety administrations research on drugged driving. We take tremendous pride in protecting americans by partnering with states to enforce strong Highway Safety laws and working to make vehicles safer. Highway fatalities have declined, traffic deaths fallen by 22 in the past decade. With more than 30,000 fatalities each year we must look at new and innovative ways to save lives. Working with our partners and other organizations we made substantial process including drunk driving and seatbelt use and applied the same approaches to emerging concerns such as distracted driving. The legalization of marijuana under state laws poses new concerns and we are working to understand these risks and develop appropriate countermeasures. Available evidence indicates alcohol is the most Common Source of driver impairment. In 2012 more than 30 of traffic deaths involved a driver with blood alcohol level at or above legal limit. Several decades of Data Collection and a well established criminal justice
Dr Reddy s Upholds Strong Compliance in 2024 biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
Divi s Laboratories Limited at its board meeting, held on May 25, 2024, Recommended a final dividend of INR 30/- per equity share of face value INR 2/- each for the financial year 2023-24, subject to.
Divi s Laboratories Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported sales was INR 23,030 million compared to INR 19,510.